Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) has earned a consensus rating of “Buy” from the seven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $19.30.

A number of equities research analysts have recently weighed in on SBPH shares. Zacks Investment Research raised HB Fuller from a “sell” rating to a “hold” rating in a research note on Wednesday, July 3rd. Chardan Capital set a $10.00 price objective on Arcimoto and gave the company a “buy” rating in a research note on Friday, April 12th. Cantor Fitzgerald set a $9.00 price objective on Evofem Biosciences and gave the company a “buy” rating in a research note on Friday, April 12th. ValuEngine downgraded Zosano Pharma from a “buy” rating to a “hold” rating in a research note on Wednesday, May 1st. Finally, Dawson James reissued a “buy” rating on shares of Spring Bank Pharmaceuticals in a research note on Monday, May 13th.

In other Spring Bank Pharmaceuticals news, Director Scott Andrew Smith purchased 12,000 shares of the company’s stock in a transaction on Friday, June 28th. The shares were bought at an average cost of $4.09 per share, with a total value of $49,080.00. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Jonathan Freve purchased 5,000 shares of the company’s stock in a transaction on Wednesday, May 29th. The stock was acquired at an average cost of $5.40 per share, for a total transaction of $27,000.00. The disclosure for this purchase can be found here. Insiders purchased a total of 42,000 shares of company stock worth $242,930 over the last three months. 12.70% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of SBPH. BNP Paribas Arbitrage SA increased its position in Spring Bank Pharmaceuticals by 1,395.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 2,946 shares of the company’s stock worth $31,000 after buying an additional 2,749 shares during the period. Rhumbline Advisers increased its position in Spring Bank Pharmaceuticals by 65.3% in the 4th quarter. Rhumbline Advisers now owns 16,771 shares of the company’s stock worth $174,000 after buying an additional 6,623 shares during the period. Dimensional Fund Advisors LP bought a new position in Spring Bank Pharmaceuticals in the 4th quarter worth approximately $206,000. Bank of New York Mellon Corp increased its position in Spring Bank Pharmaceuticals by 5.9% in the 4th quarter. Bank of New York Mellon Corp now owns 43,789 shares of the company’s stock worth $454,000 after buying an additional 2,430 shares during the period. Finally, Geode Capital Management LLC increased its position in Spring Bank Pharmaceuticals by 8.7% in the 4th quarter. Geode Capital Management LLC now owns 116,861 shares of the company’s stock worth $1,214,000 after buying an additional 9,398 shares during the period. 42.93% of the stock is currently owned by institutional investors.

Shares of SBPH traded down $0.46 during midday trading on Monday, reaching $4.66. 81,836 shares of the stock were exchanged, compared to its average volume of 57,906. Spring Bank Pharmaceuticals has a 12-month low of $3.58 and a 12-month high of $15.00. The business has a 50 day simple moving average of $4.64. The company has a debt-to-equity ratio of 0.06, a quick ratio of 12.11 and a current ratio of 12.11. The firm has a market cap of $84.19 million, a P/E ratio of -2.49 and a beta of 0.39.

Spring Bank Pharmaceuticals (NASDAQ:SBPH) last posted its quarterly earnings results on Monday, April 29th. The company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.20. As a group, sell-side analysts predict that Spring Bank Pharmaceuticals will post -2.44 earnings per share for the current year.

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops therapeutics for the treatment of viral infections, inflammatory diseases, and various cancers using small molecule nucleotide platform. Its lead product candidate is inarigivir soproxil for the treatment of chronic hepatitis B virus (HBV).

Featured Story: What is a Fiduciary?

Analyst Recommendations for Spring Bank Pharmaceuticals (NASDAQ:SBPH)

Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.